现在位置 >首页 > 时讯速递
[JAMA New Open发表论文]:基于智能手机的购物中心行走计划与每日行走步数已关闭评论
Original Investigation  Public Health January 30, 2024 A Smartphone-Based Shopping Mall Walking Program and Daily Walking Steps Yoko Matsuoka, Hiroaki Yoshida, Masamichi Hanazato JAMA Netw Open. 2024;7(1):e2353957. doi:10.1001/jamanetworkopen.2023.53957 Key Points Question  Can participating in a smartphone-based shopping mall walking program increase individuals’ daily step count? Findings  In this nationwide coh...
阅读全文
[JAMA New Open发表论文]:针对急性呼吸功能衰竭存活者的移动重症康复计划已关闭评论
Original Investigation  Critical Care Medicine January 30, 2024 Mobile Critical Care Recovery Program for Survivors of Acute Respiratory Failure: A Randomized Clinical Trial Babar A. Khan, Anthony J. Perkins, Sikandar Hayat Khan, et al JAMA Netw Open. 2024;7(1):e2353158. doi:10.1001/jamanetworkopen.2023.53158 Key Points Question  Does an intensive care unit (ICU) recovery program comprising a nurse care coordinator supporte...
阅读全文
Intensive Care Medicine在线免费阅读已关闭评论
ONLINE FIRST (FREE ACCESS) LATEST ARTICLES OriginalPrediction of post-traumatic stress disorder in family members of ICU patients: a machine learning approachDupont T. et al. EditorialBalanced solution versus saline in critically ill patients: a new piece to the puzzle!Klouche K., Monnet X. and Zarbock A. Selective digestive decontamination: We must make an international decision on this 40-year old controversyCarlet J. Selective decontamination of the dige...
阅读全文
[JAMA Surg发表论文]:首次输注全血时机与创伤患者严重出血后存活率已关闭评论
Original Investigation  January 31, 2024 Timing to First Whole Blood Transfusion and Survival Following Severe Hemorrhage in Trauma Patients Crisanto M. Torres, Kelly M. Kenzik, Noelle N. Saillant, et al JAMA Surg. Published online January 31, 2024. doi:10.1001/jamasurg.2023.7178 Key Points Question  Is the timing of first whole blood transfusion associated with improved early and late survival among adult trauma patients present...
阅读全文
[Lancet Infect Dis发表论文]:合生制剂(SIM01)用于治疗香港的2019新冠肺炎长期综合后遗症已关闭评论
ARTICLES|ONLINE FIRST A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial Raphaela I Lau, Qi Su, Ivan S F Lau, et al Lancet Infect Dis Published: December 07, 2023 DOI: https://doi.org/10.1016/S1473-3099(23)00685-0 Summary Background Post-acute COVID-19 syndrome (PACS) affects over 65 million individuals worldwide but treatment options are scarce. We aimed to as...
阅读全文
[Chest发表论文]:心源性休克患者入院和发病时间对预后的影响已关闭评论
CRITICAL CARE: ORIGINAL RESEARCH| VOLUME 165, ISSUE 1, P110-127, JANUARY 2024 Effect of Admission and Onset Time on the Prognosis of Patients With Cardiogenic Shock Michael Behnes, Jonas Rusnak, Sascha Egner-Walter, et al Chest 2024; 163: 110-127 Published: August 11, 2023 DOI:https://doi.org/10.1016/j.chest.2023.08.011 Background The spectrum of patients with cardiogenic shock (CS) has changed significantly over time. CS has become especially more common i...
阅读全文
[Lancet Infect Dis发表论文]:新冠病毒或季节性流感病毒感染住院后的长期预后已关闭评论
ARTICLES|ONLINE FIRST Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study Yan Xie, Taeyoung Choi, Ziyad Al-Aly  Lancet Infect Dis Published: December 14, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00684-9 Summary Background Previous comparative analyses of people admitted to hospital for COVID-19 versus influenza evaluated the risk of death, hospital readmission, and a narrow set of health outcome...
阅读全文
[Lancet Respir Med发表论文]:克拉霉素用于社区获得性肺炎的早期抗炎症反应已关闭评论
ARTICLES|ONLINE FIRST Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial Evangelos J Giamarellos-Bourboulis, Athanasios Siampanos, Amalia Bolanou, et al Lancet Respir Med Published: January 03, 2024 DOI: https://doi.org/10.1016/S2213-2600(23)00412-5 Summary Background Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of ...
阅读全文
[NEJM观点]:CAR-T治疗后的继发肿瘤已关闭评论
Perspective Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy Nicole Verdun, Peter Marks N Engl J Med January 24, 2024DOI: 10.1056/NEJMp2400209 Since the first such product was approved in 2017, chimeric antigen receptor (CAR) T-cell therapies have become important treatments for relapsed or refractory hematologic cancers, and the six products involving autologous CAR T cells that have been approved in the United States now cover a range of ind...
阅读全文
[Lancet Infect Dis发表论文]:低风险金黄色葡萄球菌血流感染早期口服序贯治疗的疗效与安全性已关闭评论
ARTICLES|ONLINE FIRST Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial Achim J Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, et al Lancet Infect Dis Published: January 17, 2024 DOI: https://doi.org/10.1016/S1473-3099(23)00756-9 Summary Background Staphylococcus aureus bloodst...
阅读全文
×
腾讯微博